Patents Examined by Christian Boesen
-
Patent number: 9778256Abstract: A biochip substrate which is free from cross-contamination due to spot spreading or contact with spots adjacent to each other, and a biochip using the same. A biochip substrate on which multiple valleys for immobilizing biological substances are formed so as to prevent cross-contamination due to spot spreading or contact with spots adjacent to each other, and a biochip using the same are provided. Moreover, it is found out that a desired binding in a target molecule contained in a test sample occurs at a detectable level in a solution system even in the case where a valley have such a small capacity as 1 nL to 10 nL.Type: GrantFiled: June 16, 2006Date of Patent: October 3, 2017Assignees: HIPEP LABORATORIES, NIPPON LIGHT METAL COMPANY, LTD.Inventors: Kiyoshi Nokihara, Yasuo Oka
-
Patent number: 9765132Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.Type: GrantFiled: February 1, 2013Date of Patent: September 19, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Jonathan Davis, Dasa Lipovsek, Ray Camphausen
-
Patent number: 9758554Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homolog thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of a1m.Type: GrantFiled: January 31, 2013Date of Patent: September 12, 2017Assignee: TECHNISCHE UNIVERSITAET MUENCHENInventors: Arne Skerra, Winfried Meining, Evelyn Eggenstein
-
Patent number: 9745628Abstract: Embodiments of the present invention provide substrates having controllably co-located polymers of different sequences. Methods are provided that allow the fabrication of arrays of polymers on a substrate having controllably co-located polymers in regions of the array. For example, polymers of nucleic acids and peptides having different sequences and or compositions can be co-located within a region of a substrate. Also provided are arrays of DNA polymers wherein polymers having two different sequences are co-located within a region of an array. The co-located DNA polymers can comprise complementary DNA that is able to hybridize and form double stranded DNA. Arrays having regions comprising double stranded DNA are provided.Type: GrantFiled: April 3, 2014Date of Patent: August 29, 2017Assignee: Intel CorporationInventors: Yuan Gao, Gunjan Tiwari
-
Patent number: 9738719Abstract: Methods for Identifying protein modulators of eukaryotic cells by expressing a combinatorial library of potential agonists inside a eukaryotic cell and then directly selecting for an agonist of a target molecule. Some methods involve co-culturing a cell expressing a combinatorial library of potential agonists and a second cell, and then selecting agents that modulate a phenotype of or a desired cellular response in the second cell. Preferably, the agonists are antibodies introduced into and expressed in the starting cells, such as agonist anti-EpoR, anti-TpoR, or G-CSFR antibodies. Also disclosed are methods for selecting from combinatorial antibody libraries bispecific antibodies that can regulate cell phenotypes.Type: GrantFiled: August 16, 2013Date of Patent: August 22, 2017Assignee: The Scripps Research InstituteInventors: Hongkai Zhang, Ian A. Wilson, Richard A. Lerner
-
Patent number: 9738699Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.Type: GrantFiled: May 19, 2016Date of Patent: August 22, 2017Assignee: GigaGen, Inc.Inventors: David Scott Johnson, Adam Adler, Rena Mizrahi
-
Patent number: 9733240Abstract: A generally applicable method for the selective covalent attachment of a reporter molecule to a replicating entity that allows one to obtain specific binders from a single round of library screening is disclosed. For example, selective biotinylation of phage particles and yeast cells displaying a binder to any given target can be achieved via application of a coupled enzyme reaction that includes a peroxidase, an oxidase and a catalase.Type: GrantFiled: December 14, 2012Date of Patent: August 15, 2017Assignee: Merck Patents GmbHInventors: Stefan Becker, Tim Heiseler, Alexander Maass, Harald Kolmar
-
Patent number: 9701958Abstract: The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.Type: GrantFiled: December 21, 2015Date of Patent: July 11, 2017Assignee: VACCINEX, INC.Inventors: Ernest S. Smith, Tracy Pandina, Leslie A. Croy, Mark Paris, Maurice Zauderer, Angelica Moksa, Renee Kirk
-
Patent number: 9683028Abstract: Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens.Type: GrantFiled: December 1, 2014Date of Patent: June 20, 2017Assignee: Dyax Corp.Inventors: Robert Charles Ladner, Edward Hirsch Cohen, Horacio Gabriel Nastri, Kristin L. Rookey, Rene Hoet, Hendricus Renerus Jacobus Mattheus Hoogenboom
-
Patent number: 9670481Abstract: Disclosed are methods for identifying desired members from a display libraries, including bacteriophage display libraries. Display library members can be amplified in the presence of a target compound so that cycles of selection can be rapidly completed.Type: GrantFiled: October 8, 2013Date of Patent: June 6, 2017Assignee: Dyax Corp.Inventors: Robert Charles Ladner, Shannon Hogan, Kristin L. Rookey
-
Patent number: 9670484Abstract: The invention relates to a complex comprising a phage particle, said phage particle comprising (i) a polypeptide; (ii) a nucleic acid encoding the polypeptide of (i); (iii) a connector compound attached to said polypeptide wherein said connector compound is attached to the polypeptide by at least three discrete covalent bonds. The invention also relates to libraries, and to methods for making complexes and to methods of screening using same.Type: GrantFiled: July 23, 2014Date of Patent: June 6, 2017Assignee: BICYCLE THERAPEUTICS LIMITEDInventors: Gregory Paul Winter, Christian Heinis
-
Patent number: 9670533Abstract: Methods, reagents and kits are provided for the production and use in detection assays of labeled nucleic acid molecules wherein a labeling molecule is attached directly to the 3? end of the nucleic acid molecules.Type: GrantFiled: February 24, 2014Date of Patent: June 6, 2017Assignee: Genisphere LLCInventors: Robert C. Getts, James Kadushin, Jessica Bowers
-
Patent number: 9670482Abstract: The invention relates to a method for providing a multispecific peptide ligand comprising a polypeptide covalently linked to a molecular scaffold at three or more amino acid residues and capable of binding to two or more separate targets, comprising the steps of: (a) providing a first repertoire of polypeptides, each polypeptide comprising two or more reactive groups capable of covalent linkage to a molecular scaffold, and at least one loop which comprises a sequence of two or more amino acids subtended between two of said reactive groups; (b) providing a second repertoire of polypeptides as described in (a); (c) joining at least one loop of one or more members of the first repertoire to at least one loop of one or more members of the second repertoire to form at least one polypeptide comprising two loops, and (d) conjugating the composite polypeptide(s) to a molecular scaffold at at least three amino acid positions.Type: GrantFiled: November 26, 2013Date of Patent: June 6, 2017Assignee: BICYCLE THERAPEUTICS LIMITEDInventors: Gregory Paul Winter, Christian Heinis, Elise Bernard, David Loakes, John Tite, Marina Vaysburd, Daniel Paul Teufel, Lutz Riechmann
-
Patent number: 9657288Abstract: The invention relates to a complex comprising a phage particle, said phage particle comprising (i) a polypeptide; (ii) a nucleic acid encoding the polypeptide of (i); (iii) a connector compound attached to said polypeptide wherein said connector compound is attached to the polypeptide by at least three discrete covalent bonds. The invention also relates to libraries, and to methods for making complexes and to methods of screening using same.Type: GrantFiled: August 22, 2013Date of Patent: May 23, 2017Assignee: BICYCLE THERAPEUTICS LIMITEDInventors: Gregory P. Winter, Christian Heinis
-
Patent number: 9657289Abstract: An object of the invention is to provide a peptide having a stabilized secondary structure. The present invention provides a peptide having a secondary structure stabilized by a crosslinked structure and containing at least one combination of a special amino acid of the formula (I): (wherein, (A) represents a single bond or a linking group having, in the main chain thereof, from 1 to 10 atoms; (B) represents a group containing at least one ? bond; (C) represents a hydrogen atom or an alkyl group which may be substituted with a substituent; and X represents a group substitutable by a substitution reaction with a sulfanyl group) and an amino acid having, in the side chain thereof, a sulfanyl group; and having the crosslinked structure formed through a thioether bond between the side chain of the special amino acid residue and the sulfanyl group.Type: GrantFiled: December 5, 2011Date of Patent: May 23, 2017Assignee: The University of TokyoInventors: Hiroaki Suga, Takashi Higuchi
-
Patent number: 9651559Abstract: The present application relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.Type: GrantFiled: December 1, 2014Date of Patent: May 16, 2017Assignee: F-star Biotechnologische Forschungs— und Entwicklungsges.m.b.HInventors: Gottfried Himmler, Geert Mudde, Gerda Redl, Florian Ruker, Gordana Wozniak-Knopp
-
Patent number: 9644239Abstract: The present invention provides methods for predicting the risk of an individual developing antibodies to factor VIII by identifying a single nucleotide polymorphism of an immune response or immune modifier gene. The invention further provides oligonucleotides, diagnostic kits, microarrays, and isolated nucleic acids comprising single nucleotide polymorphisms of immune response or immune modifier genes.Type: GrantFiled: August 10, 2011Date of Patent: May 9, 2017Inventors: Jan Astermark, Erik Berntorp
-
Patent number: 9644203Abstract: The present invention relates to methods for screening a polypeptide for desired activity against a target molecule. In particular, the present invention relates to methods for screening a polypeptide for desired activity against a target molecule by expressing the polypeptide in a Gram-negative bacterial cell and permeabilising the cell. The invention also relates to methods of packaging gene libraries in a bacterial cell.Type: GrantFiled: December 27, 2013Date of Patent: May 9, 2017Assignee: Affinity Biosciences Pty LtdInventors: Matthew Beasley, Ben Kiefel
-
Patent number: 9645146Abstract: Aspects of the invention provide compositions and methods for displaying engineered polypeptides on a cell surface. According to aspects of the invention, immobilized polypeptides can be screened to identify one or more variants having one or more functional or structural properties of interest. Aspects of the invention provide composition and methods for producing engineered protein or protein variants having a functional or a structural property of interest.Type: GrantFiled: March 26, 2014Date of Patent: May 9, 2017Assignee: Agenus, Inc.Inventors: James A. Rakestraw, Stan I. Letovsky, Shaun Lippow
-
Patent number: 9644201Abstract: The invention relates to a method for modifying one or more peptide ligands, comprising polypeptides covalently linked to a molecular scaffold at two or more amino acid residues, comprising the steps of providing one or more peptide ligands, wherein the polypeptide comprises two or more reactive groups which form a covalent linkage to the molecular scaffold, and at least one loop which comprises a sequence of two or more amino acids subtended between two of said reactive groups; exposing the peptide ligands to one or more proteases; and sorting the ligands according to the extent of proteolytic cleavage.Type: GrantFiled: April 1, 2014Date of Patent: May 9, 2017Assignee: BICYCLE THERAPEUTICS LIMITEDInventors: Gregory Paul Winter, Christian Heinis, Elise Bernard, David Loakes, Marina Vaysburd